Publications by authors named "Douglas Jacobstein"

Claim this Profile
U
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
Joel R Rosh, Dan Turner, Anne Griffiths, Stanley A Cohen, Douglas Jacobstein

J Crohns Colitis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Stephen B Hanauer, William J Sandborn, Brian G Feagan, Christopher Gasink, Douglas Jacobstein

J Crohns Colitis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
Katherine Li, Joshua R Friedman, Daphne Chan, Paul Pollack, Feifei Yang, Douglas Jacobstein

Gastroenterology· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Douglas Jacobstein

Gastroenterology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
Bruce E Sands, Chenglong Han, Christopher Gasink, Douglas Jacobstein, Philippe Szapary

J Crohns Colitis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Omoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary

Gastroenterology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang

N Engl J Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retention of Endogenous Viable Cells Enhances the Anti-Inflammatory Activity of Cryopreserved Amnion.
Yi Duan-Arnold, Alexandra Gyurdieva, Amy Johnson, Thomas E Uveges, Douglas A Jacobstein

Adv Wound Care (New Rochelle)· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble Factors Released by Endogenous Viable Cells Enhance the Antioxidant and Chemoattractive Activities of Cryopreserved Amniotic Membrane.
Yi Duan-Arnold, Alexandra Gyurdieva, Amy Johnson, Douglas A Jacobstein, Alla Danilkovitch

Adv Wound Care (New Rochelle)· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective analysis of a human cellular repair matrix for the treatment of chronic wounds.
Matthew Regulski, Douglas A Jacobstein, Russell D Petranto, Vincent J Migliori, Girish Nair

Ostomy Wound Manage· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of immunomodulator use as early therapy in pediatric Crohn's disease.
Douglas A Jacobstein, Petar Mamula, Jonathan E Markowitz, Mary Leonard, Robert N Baldassano

J Clin Gastroenterol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
Douglas A Jacobstein, Jonathan E Markowitz, Barbara S Kirschner, George Ferry, Stanley A Cohen

Inflamm Bowel Dis· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-month-old with persistent diarrhea.
Douglas Jacobstein, Jonathan Markowitz, Petar Mamula

MedGenMed· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance.
Douglas A Jacobstein, Robert N Baldassano

Inflamm Bowel Dis· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis